Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease

Movement Disorders

Volumn 12, Issue 5, 1997, Pages 760-763

  Le Couteur, David G ^a,b   Leighton, Peter W ^a   McCann, Sally J ^a   Pond, Susan M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Dopamine transporter; Parkinson's disease; Polymorphism; Variable number tandem repeat

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE TRANSPORTER;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; VARIABLE NUMBER OF TANDEM REPEAT;

AGE OF ONSET; AGED; ALLELES; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DISEASE SUSCEPTIBILITY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; ODDS RATIO; PARKINSON DISEASE; POLYMORPHISM, GENETIC; REPETITIVE SEQUENCES, NUCLEIC ACID;

EID: 0030921878     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870120523     Document Type: Article

References (30)

1. Duvoisin RC. The genetics of Parkinson's disease: a review. Adv Neurol 1993;60:306-315.
2. Lazzarinni AM, Myers RH, Zimmerman TR, et al. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology 1994;44:499-506.
3. Golbe LI, Di lorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990;27:276-282.
4. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992;339:1017-1018.
5. Smith CA, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-1377.
6. Kurth JH, Kurth MC, Poduslo SE, Schwankhaus JD. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993;33:368-372.
7. Ho SL, Kapadi AL, Ramsden DB, Williams AC. An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol 1995;37:403-405.
8. Bandmann O, Davis MB, Marsden CD, Harding AE. Sequence of the Superoxide dismutase 1 (SOD 1) gene in familial Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:90-91.
9. Marder K, Maestre G, Cote L, et al. The apolipoprotein ε4 allele in Parkinson's disease with and Without dementia. Neurology 1994; 44:1330-1331.
10. Nanko S, Ueki A, Hattori M, et al. No allelic association between Parkinson's disease and dopamine D2, D3, and D4 receptor gene polymorphisms. Am J Med Genet 1994;54:361-364.
11. Tanner CM. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci 1989;12:49-54.
12. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983;219:979-980.
13. Tanner CM, Zack MM. Comorbidity as it relates to the etiology of Parkinson's disease. In: Ellenberg JH, Koller WC, Langston JW, eds. Etiology of Parkinson's disease. New York: Marcel Dekker, 1995:245-275.
14. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993;61:1191-1206.
15. +: uptake and velocity in nonneuronal COS cells expressing dopamine transporter cDNA. Ann Neurol 1992;43:109-111.
16. Hitri A, Hurd YL, Wyatt RJ, Deutsch SI. Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin Neuropharmacol 1994;17: 1-22.
17. Hornykiewicz O. The primary site of dopamine neuron damage in Parkinson's disease: substantia nigra of striatum. Mov Disord 1992;7:288.
18. Vandenbergh DJ, Persico AM, Hawkins AL, et al. Human dopamine transporter gene maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992;14:1104-1106.
19. Cook EH, Stein MA, Krasowski MD, et al. Association of attention deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995;56:993-998.
20. Muramatsu T, Higuchi S. Dopamine transporter gene polymorphism and alcoholism. Biochem Biophys Res Commun 1995;211: 28-32.
21. Persico AM, Vandenbergh DJ, Smith SS, Uhl GR. Dopamine transporter gene polymorphisms are not associated with polysubstance abuse. Biol Psychiatry 1993;34:265-267.
22. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease: clinical and theoretic implications. Ann Neurol 1992;32 (suppl):S125-S127.
23. Douglas AM, Georgalis AM, Benton LT, Canavan KL, Atchison BA. Purification of human leucocyte DNA: proteinase K is not necessary. Anal Biochem 1992;201:362-365.
24. Gerlernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 1994;11:195-200.
25. + transport. Synapse 1993;15:58-62.
26. Krontiris TG. Minisatellites and human disease. Science 1995;269: 1682-1683.
27. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nature Genet 1995;9:293-298.
28. Ohta S, Kohno M, Makino Y, Tachikawa O, Hirobe M. Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in the human brain: relation to Parkinson's disease. Biomed Res 1987; 8:453-456.
29. +analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 1995;45: 2240-2245.
30. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812.